Login to Your Account



Clinic Roundup


Tuesday, November 27, 2012
The Belgian Federal Agency for Medicines and Health Products gave authorization to Cardio3 BioSciences, of Mont-Saint-Guibert, Belgium, to begin a Phase III trial of C3BS-CQR-1, an autologous stem cell therapy, for congestive heart failure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription